HUMA Stock Analysis: Buy, Sell, or Hold?
HUMA - Humacyte, Inc. Common Stock
$0.69
0.00 (-0.36%)
▼
5d:
-10.3%
30d:
-48.42%
90d:
+7.1%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 10, 2026
26d
Get Alerted When HUMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called HUMA this week
67% bullish • 1 bearish
67% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HUMA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: HUMA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: HUMA is currently trading at $0.69, which is considered slightly low relative to its 30-day fair value range of $0.66 to $1.19.
Technical Outlook: Technically, HUMA is in a strong downtrend. The price is currently testing key support at $1.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HUMA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $2.05 (+196.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HUMA is in a strong downtrend. The price is currently testing key support at $1.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HUMA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $2.05 (+196.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.66 -
$1.19
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 196.6% below Wall St target ($2.05)
- CAUTION: 5-day price weakness (-10.3%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.66 -
$1.19
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.10
Resistance Level
$1.53
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.88
Wall Street Target
$2.05
(+196.6%)
Revenue Growth (YoY)
-4.3%
Share & Embed Analysis
Last updated: July 14, 2026 3:59 AM ET
Data refreshes hourly during market hours. Next update: 4:58 AM
Data refreshes hourly during market hours. Next update: 4:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HUMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 49 HOLD |
|
CNTA
Centessa Pharmaceuticals… |
STRONG BUY
11 analysts |
$44 | 61 BUY |
